Michael A. Nauck
Ruhr University Bochum
Internal medicineEndocrinologyPlaceboGastric inhibitory polypeptideGlucagon-like peptide-1Type 2 diabetesPostprandialGlucagonIncretinInsulinMetforminExenatideLiraglutideType 2 Diabetes MellitusGastric emptyingDiabetes mellitusHormoneMedicineBiologyGastroenterology
397Publications
97H-index
38.9kCitations
Publications 420
Newest
#1Daniel R. Quast (RUB: Ruhr University Bochum)H-Index: 2
#2Michael A. Nauck (RUB: Ruhr University Bochum)H-Index: 97
Last. Juris J. Meier (RUB: Ruhr University Bochum)H-Index: 73
view all 0 authors...
AIM To clarify the distinct effects of a long-acting (liraglutide) and a short-acting (lixisenatide) glucagon-like peptide-1 receptor agonist (GLP-1 RA) on macronutrient intake, gastrointestinal side effects and pancreas function. MATERIALS AND METHODS Fifty participants were randomized to either lixisenatide or liraglutide for a treatment period of 10 weeks. Appetite, satiety, macronutrient intake, gastrointestinal symptoms and variables related to pancreatic function and gastric emptying were ...
Source
#1Michael A. Nauck (RUB: Ruhr University Bochum)H-Index: 97
#2Jakob Wefers (RUB: Ruhr University Bochum)H-Index: 1
Last. Juris J. Meier (RUB: Ruhr University Bochum)H-Index: 73
view all 0 authors...
Despite the successful development of new therapies for the treatment of type 2 diabetes, such as glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 inhibitors, the search for novel treatment options that can provide better glycaemic control and at reduce complications is a continuous effort. The present Review aims to present an overview of novel targets and mechanisms and focuses on glucose-lowering effects guiding this search and developments. We discuss not ...
Source
The first clinical study of an oral small-molecule GLP-1 receptor agonist suggests effective glycemic control and weight loss in patients with type 2 diabetes.
Source
#1Michael A. NauckH-Index: 97
Last. Christoph KapitzaH-Index: 22
view all 0 authors...
DPP-4 inhibitors may prevent hypoglycemic episodes in insulin-treated type 2 diabetes (T2D), but mechanisms are unclear. 20 T2D patients treated with basal insulin and metformin (± other agents) were recruited for two randomized treatments (placebo or 100 mg/d sitagliptin) in addition to insulin glargine/metformin; 17 completed (3 women, 14 men; age 57 ± 7 yrs.; BMI 28.8 ± 3.9 kg/m2; HbA1c 7.4 ± 0.7 %). After titrating fasting plasma glucose (PG) to 90-110 mg/dl, patients were observed during a ...
Source
#1Anna M. Lindmeyer (RUB: Ruhr University Bochum)H-Index: 1
#2Michael A. Nauck (RUB: Ruhr University Bochum)H-Index: 97
Last. Juris J. Meier (RUB: Ruhr University Bochum)H-Index: 73
view all 3 authors...
Eine Patientin wurde aufgrund rezidivierender postprandialer Hypoglykamien nach Roux-en-Y-Magenbypass mit Diazoxid behandelt, nachdem eine Ernahrungsumstellung keine Symptomlinderung erzielt hatte. Nach Eindosierung von Diazoxid mit guter Akutvertraglichkeit wurde die Patientin entlassen. Eine Woche nach Therapieeinleitung kam es zu einer Lymphadenopathie und Panzytopenie. Es fanden sich keine Hinweise auf das Vorliegen eines Infekts. Nach Absetzen von Diazoxid sistierten die Beschwerden. Unser ...
Source
#1Kamlesh Khunti (University of Leicester)H-Index: 96
#2Melanie J. Davies (University of Leicester)H-Index: 95
Last. Michael A. Nauck (RUB: Ruhr University Bochum)H-Index: 97
view all 4 authors...
Cardiometabolic conditions, including type 1 and type 2 diabetes mellitus, are associated with severe COVID-19 and long COVID. Interventions to target multiple risk factors, combined with use of novel glucose-lowering agents that improve metabolic function and the key processes that are impaired in COVID-19, should be the preferred therapeutic options for management of people with long COVID.
Source
#1Jesse RothH-Index: 83
#2Frances M. AshcroftH-Index: 104
Last. Mark A. AtkinsonH-Index: 113
view all 18 authors...
Marking insulin's centennial, we share stories of researchers and clinicians whose seminal work has advanced our understanding of insulin, islet biology, insulin resistance, and diabetes. The past century of pursuing the "hormone of hormones" and advancing diabetes therapies is replete with stories of collaboration, perseverance, and triumph.
Source
#1Michael A. Nauck (RUB: Ruhr University Bochum)H-Index: 97
#2Daniel R. Quast (RUB: Ruhr University Bochum)H-Index: 2
Last. Juris J. Meier (RUB: Ruhr University Bochum)H-Index: 73
view all 4 authors...
Abstract Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide b.i.d. first approved to treat type 2 diabetes in 2005 have been further developed to yield effective compounds/preparations that have overcome the original problem of rapid elimination (short half-life), initially necessitating short intervals between injections (twice daily for exenatide b.i.d.). Scope of review To summarize current knowledge about GLP-1 receptor agonist. Major conclusions At present, GLP-1 RAs are injected...
13 CitationsSource
To exclude an excess risk of cardiovascular (CV) events, CV outcomes trials (CVOTs) have assessed the effects of new glucose-lowering therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs), in patients with type 2 diabetes and established CV disease or CV risk factors. The CV safety of semaglutide vs. placebo, when added to standard care, was evaluated in the SUSTAIN 6 trial for the formulation administered once-weekly subcutaneously and in PIONEER 6 for the new once-daily ora...
Source
#1Michael A. Nauck (RUB: Ruhr University Bochum)H-Index: 97
#2Anna M. Lindmeyer (RUB: Ruhr University Bochum)H-Index: 1
Last. Juris J. Meier (RUB: Ruhr University Bochum)H-Index: 73
view all 4 authors...
Background:Twenty-four hour fasting periods are being used to scrutinize basal insulin infusion rates for pump-treated patients with type 1 diabetes.Methods:Data from 339 consecutive in-patients wi...
3 CitationsSource